Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report

A remarkable concurrence of an EGFR mutation and an EML4-ALK fusion (double positive) occasionally occurs within a narrow number of patients. Previous studies using targeted therapy on EGFR/ALK co-mutated patients have commonly focused on single tyrosine kinase inhibitors (TKIs) or on the sequential...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongbiao, Zhu, Sujuan, Li, Zhifeng, Qi, Xiaofang, Zhang, Liwen, Ke, Leiyu, Lin, Yingcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439748/
https://www.ncbi.nlm.nih.gov/pubmed/36107507
http://dx.doi.org/10.1097/MD.0000000000030316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439748/
https://www.ncbi.nlm.nih.gov/pubmed/36107507
http://dx.doi.org/10.1097/MD.0000000000030316

Ejemplares similares